Novel Agents and Future Perspectives on Theranostics.
Novel Agents and Future Perspectives on Theranostics.
复制标题
DOI：
10.1016/j.semradonc.2020.07.010
复制
发表时间：
2021-01
影响因子：
3.5
通讯作者：
Pandit-Taskar N
中科院分区：
文献类型：
--
作者：
Solnes LB;Shokeen M;Pandit-Taskar N
在当前的精准医学时代，人们对放射性药物治疗和治疗学重新产生了兴趣。FDA批准了生长抑素受体定向治疗和去甲肾上腺素转运体靶向131I-MIBG治疗，以及极具前景的β和α发射器标记PSMA前列腺癌定向治疗的快速进展，在实践中刺激了临床影响的变化。许多新的策略正在被探索，新的放射性药物治疗剂包括基于肽的配体以及抗体或抗体片段正在临床前或早期临床试验中开发。虽然β粒子发射器最常用于靶向放疗和放射免疫靶向，但由于高能粒子在较短的组织穿透范围内，因此对邻近正常组织的毒性较低，因此对α粒子发射器产生更大的电离事件密度，导致双链DNA损伤和簇断裂增加，因此对α粒子发射器的兴趣正在增加。
In the current era of precision medicine, there is renewed interest in radiopharmaceutical therapy and theranostics. The approval of somatostatin receceptor directed therapy and norepinephrine transporter targeted 131I-MIBG therapies by the FDA and the rapid progress of highly promising beta and alpha emitter tagged PSMA directed therapy of prostate cancer have stimulated clinically impactful changes in practice. Many novel strategies are being explored and novel radiopharmaceutical therapeutic agents including peptide based ligands as well as antibodies or antibody fragments are being developed preclinically or are in early phase clinical trials. While beta particle emitters have most commonly been used for targeted radiotherapy and radioimmunotargeting, there is an emerging interest in alpha emitters that cause greater density of ionization events leading to increased double-strand DNA damage and cluster breaks because of the high-energy particles within a shorter tissue range of penetration and thereby lower toxicity to adjacent normal tissues.
登录
查看更多内容
影响因子：
7.2
作者：
Dawicki, Wojciech;Allen, Kevin J. H.;Dadachova, Ekaterina
通讯作者：
Dadachova, Ekaterina
影响因子：
4.9
作者：
Beaino W;Nedrow JR;Anderson CJ
通讯作者：
Anderson CJ
影响因子：
2.1
作者：
Darson, MF;Pacelli, A;Bostwick, DG
通讯作者：
Bostwick, DG
影响因子：
45.3
作者：
Brouwers, AH;Mulders, PFA;Oyen, WJG
通讯作者：
Oyen, WJG
影响因子：
9.3
作者：
Choi, Jaeyeon;Beaino, Wissam;Anderson, Carolyn J.
通讯作者：
Anderson, Carolyn J.